FLT3 and acute myeloid leukemia: Five patients (3%) with FMS-related tyrosine kinase 3—internal tandem duplication (FLT3-ITD)-mutated AML additionally received off-label treatment with Sorafenib in a dosage of 2 × 400 mg orally per day [25].